Leptin-targeting drugs can affect different cell types, including endothelial cells, adipocytes [219], cancer cells with a less aggressive phenotype, and immune cells by decreasing macrophage recruitment, phagocytic activity, and cytokine production [209]. Here, LEP is linked to cancer.